Protara Therapeutics, Inc.
TARA
Last
$2.71
Day
+2.3%
1y
-52.8%
5y
-60.5%
52w
-66.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0930d
EMA 21
3.11
EMA 50
3.51
EMA 200
4.29
20d high
-34.0%
5y high
-74.7%
5y range
17th
Positions held
Your positionsTARA isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-24
Hold
avoid
Signal
Strong Sell
Target
$3.07
Stop
$2.30
Stop distance
15.1%
Target vs last
+13.3%
Fundamentals
| Market cap | $156.60M | Enterprise value | $16.86M | Trailing P/E | — | Forward P/E | -1.57 |
| PEG | — | Price / book | 0.97 | Beta | 1.47 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -45.8% | ROA | -28.8% | Debt / equity | 0.02 |
| Current ratio | 10.97 | Free cash flow | -$40.49M | Analyst recommendation | strong_buy | Mean target | $25.71 |
| 52w high | $7.82 | 52w low | $2.51 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$21.7M | -$17.8M | -$17.3M | -$13.3M | -$15.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$23.3M | -$19.6M | -$19.1M | -$14.8M | -$16.6M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$57.4M | -$44.6M | -$40.4M | -$66.0M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$64.5M | -$49.2M | -$43.6M | -$37.5M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-08 · Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-11 · Protara Therapeutics: Q2 Earnings Snapshot
2026-08-11 · Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
2026-07-21 · What Makes Protara Therapeutics (TARA) a New Buy Stock
Price (daily)
Full chart · RSI · MACD · patternsTARA · daily-28.0% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin